Dr. Jung Lee Joins Harbour Antibodies as Vice President of Business Development
SHANGHAI & ROTTERDAM, the Netherlands & CAMBRIDGE, Mass. July 13, 2018
Harbour Antibodies US, a subsidiary of Harbour Biomed, announced today that it has appointed Jung Lee, Ph.D. as its Vice President of Business Development. In this role, Dr. Lee will lead the company’s efforts in out-licensing of the H2L2 and HCAb Harbour transgenic mouse platforms and developing strategic collaboration and partnerships in both US and EU.
“Dr. Lee’s expertise and experience were a perfect fit for Harbour Antibodies US, as we continue to unlock the vast potential of our transgenic technology platforms and develop new biologics,” said Jingsong Wang, MD, Ph.D., the Chairman and Chief Executive Officer of Harbour Biomed. “Dr. Lee will play a critical role as we advance our next-generation transgenic mouse platforms. He will also be an important leader in generating collaborations and partnerships for our rapidly emerging biologic pipeline.”
Previously, Dr. Lee worked with a gene therapy company, establishing a joint venture in Spain. Prior to the gene therapy business development efforts, he was the Partnering & Strategy head for Antibody Discovery and Protein Engineering, Biopharmaceutical Development and Biosuperior for MedImmune (the global biologics arm of AstraZeneca). He was responsible for licensing in and acquiring of all technologies that would be beneficial in developing any biologic drugs for the company.
Prior to MedImmune, Dr. Lee was Executive Director at Martek Biosciences Corporation (acquired by DSM in year 2010); overseeing numerous activities such as business development, innovation, and sales & marketing in Japan and Korea Dr. Lee also managed the Martek’s fluorescence pigment business unit until it was spun out. Before his career in business development, he held key research positions and led numerous research programs in both GSK and Johnson & Johnson. He has published fourteen research articles in internationally recognized journals, many of them as a first author, and written a review chapter. He was a co-inventor to twenty granted patents and patent applications.
Dr. Lee earned a Ph.D. from the University of Michigan in Medicinal Chemistry and was a post-doctoral fellow at M.I.T.
About Harbour BioMed
Harbour BioMed is a global biopharmaceutical company discovering and developing innovative therapeutics for oncology and immunological diseases. The company’s discovery and development programs are built around its two patented transgenic mouse platforms (Harbour Mice) for human antibody therapeutic discovery. The company is building its proprietary pipeline through its innovative internal discovery programs, and through in-licensing clinical stage assets that strategically fit its internal portfolio. Harbour BioMed also licenses the platforms to companies and academic institutions through its Harbour Antibodies subsidiary. For additional information, please visit harbourbiomed.com.
About Harbour Mice
A fully owned subsidiary of Harbour BioMed, Harbour Antibodies owns two strains of transgenic mice for generating human therapeutic antibodies: (1) mice that generate antibodies comprised of two heavy chains and two light chains (H2L2) with fully human variable regions; and (2) mice that generate novel “heavy chain only” antibodies (HCAb). The HCAb mice enable the development of antibody fragment-based therapeutics such as nanobodies, bi-specific antibodies and CAR-T with favorable biophysical properties. For additional information, please visit harbourantibodies.com.